• agentshags
    link
    fedilink
    English
    arrow-up
    3
    ·
    1 year ago

    Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, targets a type of protein in the brain called beta-amyloid, long thought by scientists to be one of the underlying causes of Alzheimer’s disease.